Detalhe da pesquisa
1.
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol
; 262(1): 43-51, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37668741
2.
INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
Retina
; 44(4): 714-722, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016089
3.
SCLERAL THICKNESS IN THE FELLOW EYES OF PATIENTS WITH UNILATERAL CENTRAL SEROUS CHORIORETINOPATHY.
Retina
; 43(9): 1573-1578, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37262427
4.
Scleral Thickness in Simple Versus Complex Central Serous Chorioretinopathy.
Am J Ophthalmol
; 261: 103-111, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38281567
5.
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan.
Sci Rep
; 14(1): 11681, 2024 05 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38778065
6.
Clinical Characteristics and Progression of Geographic Atrophy in a Japanese Population.
Ophthalmol Retina
; 7(10): 901-909, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37302656
7.
Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan.
Sci Rep
; 13(1): 8747, 2023 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37253802